At first, 3 patients will be enrolled in Group 1 and administered a single intravitreal injection of TLC399 (ProDex), i.e., 0.36 mg dexamethasone sodium phosphate (DSP) with 100 mM phospholipid (PL) (30 µL) on Day 0. After the intravitreal injection, each patient will be observed for 4 weeks for Dose Limiting Toxicities (DLTs). If 1 of 3 patients develops Dose Limiting Toxicities (DLTs), the cohort will be expanded to a maximum of 6 patients (another 3 patients added subsequently). If exactly 1 of the 6 patients experiences Dose Limiting Toxicities (DLTs), then escalation to the next dose level (i.e., Group 2) will occur. If more than 1 patient out of the 6 develops Dose Limiting Toxicities (DLTs), the study will be temporarily suspended. The protocol will be amended and new doses identified to restart the study. If none of the first 3 patients experiences a Dose Limiting Toxicity (DLT), then dose escalation will proceed to the next cohort of patients (i.e., Group 2).